Phase2, single arm investigator initiated study of Atezolizumab in advanced or recurrent non-small cell lung cancer patients for biomarker research
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2018
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2017 Status changed from not yet recruiting to recruiting.
- 03 Nov 2017 New trial record